<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374712</url>
  </required_header>
  <id_info>
    <org_study_id>P031010</org_study_id>
    <secondary_id>CRC 03161</secondary_id>
    <nct_id>NCT00374712</nct_id>
  </id_info>
  <brief_title>Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia</brief_title>
  <official_title>Study of Klotho Gene Polymorphisms in the Regulation of Serum Phosphate Levels in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic kidney disease (CKD) and those with end-stage renal disease (ESRD)
      undergoing renal replacement therapies show elevated serum phosphate levels which predispose
      them to cardiovascular calcifications and high risks of death from cardiovascular diseases.
      However, in certain patients hyperphosphatemia is not related to dialysis insufficiency,
      excessive daily dietary phosphorus intake or high serum parathyroid hormone (PTH) levels,
      suggesting that other mechanisms could be involved. Transgenic mice lacking the klotho gene
      showed a phenotype which resembles that of dialyzed ESRD patients, in the sense that they
      have hyperphosphatemia, vascular calcifications, and a short lifespan. This study will
      analyze whether functional polymorphisms or variants in the human klotho gene are associated
      with hyperphosphatemia in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The entire coding region of the klotho gene will be sequenced looking for functional variants
      and polymorphisms that differentiate two groups of adult dialyzed ESRD patients, matched for
      age and gender, and with comparable values for dialysis dose and daily protein intake. These
      two groups consist of one group of 20 adult, dialyzed patients with serum phosphate levels &gt;
      2.50 mM compared to another group of 20 adult, dialyzed ESRD patients with serum phosphate
      levels &lt; 1.50 mM. The results of this study will allow to determine whether there is a
      relationship between extreme hyperphosphatemia and klotho gene polymorphisms in dialysed ESRD
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated
  </why_stopped>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Hyperphosphatemia</condition>
  <condition>Renal Osteodystrophy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult, end-stage renal disease patients treated by standard hemodialysis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1

          -  Stable hemodialysis patients for at least 3 months

          -  Phosphatemia &gt; 2.5 mM

          -  Kt/V &gt; 1.2

          -  Total weekly phosphate removal &gt; 75 millimoles

        Group 2

          -  Stable hemodialysis patients for at least 3 months

          -  Phosphatemia &lt; 1.5 mM

          -  Kt/V &gt; 1.2

          -  Total weekly phosphate removal &gt; 25 millimoles

        Exclusion Criteria:

          -  Age &gt; 80 years

          -  Insufficient dialysis dose (Kt/V &lt; 1.2)

          -  Total weekly phosphate removal &lt; 25 mM

          -  Problems with vascular access for hemodialysis (central catheter, arteriovenous [A-V]
             fistula dysfunction)

          -  Methods of dialysis different than the classical hemodialysis (peritoneal,
             hemofiltration, or hemodiafiltration with or without acetate)

          -  Intolerance or allergy to ARYLANE M9 dialyzers

          -  Hypocalcemia &lt; 2.0 mmol/liter

          -  Hypophosphatemia &lt; 0.6 mmol/liter

          -  Daily protein intake &lt; 0.6 g/kg/j

          -  Parathyroidectomy at least 3 months prior to the study

          -  Evolutive neoplasia with or without secondary lytic bone lesions

          -  Intestinal malabsorption

          -  Alcoholism

          -  Corticotherapy

          -  Treatment by bisphosphonates, fluor or recombinant PTH

          -  Malnutrition (body mass index [BMI] &lt; 15)

          -  Amputation of lower members (&gt; 10% of total body)

          -  Prolonged immobilization

          -  Secondary hyperparathyroidism (PTH &gt; 1400 pg/ml)

          -  Vitamin D deficiency (25OHD3 &lt; 10 ng/ml)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo URENA TORRES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique de l'Orangerie, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique de l'Orangerie - Service de Néphrologie et Dialyse</name>
      <address>
        <city>Aubervilliers</city>
        <zip>93300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Prié D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens. 2005 Jul;14(4):318-24. Review.</citation>
    <PMID>15930998</PMID>
  </results_reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2006</study_first_posted>
  <last_update_submitted>November 6, 2007</last_update_submitted>
  <last_update_submitted_qc>November 6, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2007</last_update_posted>
  <keyword>Phosphate</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Klotho</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

